California, USA-based BioMarin Pharmaceutical says that Firdapse (3,4-diaminopyridine) is now commercially available in the European Union for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
Launching immediately in Germany and the UK, the company expects to subsequently debut Firdapse in all major European markets by the end of 2010. The drug received marketing approval in the EU for the treatment of LEMS in December 2009 and this is the first approved treatment for this indication, thereby conferring orphan drug protection and providing 10 years of market exclusivity in Europe.
"The launch of Firdapse brings the first specifically approved treatment option for LEMS to patients in the EU and marks our fourth commercial product on the market. We look forward to meeting with the FDA [Food and Drug Administration] in the second quarter of 2010 to determine the necessary regulatory path for Firdapse in the USA, and we also continue to evaluate the best development strategy for this product in other indications in the USA and Europe," said Jean-Jacques Bienaime, chief executive of BioMarin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze